source
- Incyte agrees to acquire Vega Therapeutics for $1.25 billion upfrontIncyte announced it will purchase Vega Therapeutics, a subsidiary of Star Therapeutics, in a transaction that includes an upfront payment of $1.25 billion. The acquisition gives Incyte control of…
- Incyte CEO frames $2 billion Vega acquisition as key to post-Jakafi strategyIncyte's chief executive Bill Meury said the company’s recent $2 billion purchase of Vega is intended to expand its blood‑disorder pipeline beyond the already‑approved Jakafi. Meury, who has previ…